From Opinion to Precision: How Elasticity™ Aligns Pricing and Value Strategy

𝗬𝗼𝘂𝗿 𝗣𝗿𝗼𝗱𝘂𝗰𝘁’𝘀 𝗩𝗮𝗹𝘂𝗲 𝗜𝘀𝗻’𝘁 𝗦𝘁𝗮𝘁𝗶𝗰. 𝗦𝗼 𝗪𝗵𝘆 𝗜𝘀 𝗬𝗼𝘂𝗿 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆?

Imagine your Commercial and Medical teams are preparing for launch. You’ve got an asset with differentiated clinical value—but the price is still up for debate. The Commercial team needs to justify a premium over a competitor. The Medical team wants to validate value based on real-world access drivers. Here’s where Elasticity™ steps in. Built into eMAX Health Systems' MAVA platform, 𝗘𝗹𝗮𝘀𝘁𝗶𝗰𝗶𝘁𝘆™ 𝗹𝗲𝘁𝘀 𝗯𝗼𝘁𝗵 𝘁𝗲𝗮𝗺𝘀 𝘁𝗲𝘀𝘁 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝘀𝗰𝗲𝗻𝗮𝗿𝗶𝗼𝘀 𝘀𝗶𝗱𝗲-𝗯𝘆-𝘀𝗶𝗱𝗲, 𝗮𝗻𝗱 𝘁𝗵𝗲𝗻 𝗺𝗼𝗱𝗲𝗹 𝘃𝗮𝗹𝘂𝗲 𝗮𝗻𝗱 𝗽𝗿𝗶𝗰𝗲 𝗶𝗻 𝗿𝗲𝗮𝗹 𝘁𝗶𝗺𝗲.

• Commercial teams can simulate discounting thresholds using validated product analogs.

• Medical teams can quantify value drivers and build a value index based on payer-tested criteria.

• Together, they can align on what the market will bear and offer clarity before the stakes get high.

Elasticity™ is especially impactful in areas where access complexity meets pricing pressure:

• Oncology – crowded pipelines, high-cost therapies, complex value frameworks

• Rare Disease – limited comparators, extreme price sensitivity, payer skepticism

• Cell & Gene Therapy – launch pricing and value-based contracting are hot-button issues

• Immunology & Rheumatology – highly competitive categories with tough access barriers

No more siloed spreadsheets. No more guesswork. Just a shared interface that’s ready when you are. It’s how leading pharma teams move from opinion to precision. Let us show you how Elasticity™ makes it possible. Schedule a demo